|
WO2015160703A1
|
|
Treatment methods for gut-mediated hiv immune dysfunction
|
|
US2014248641A1
|
|
Cloned glucagon-like peptide-2 receptors
|
|
WO2013033227A2
|
|
Injectable drug cartridge container
|
|
EP2569001A2
|
|
Methods for treatment or prophylaxis of kidney or liver dysfunction
|
|
EP2099444A1
|
|
Use of d-serine derivatives for the treatment of anxiety disorders
|
|
AU2007221967A1
|
|
Inorganic ion receptor-active compounds
|
|
CA2623250A1
|
|
Fluorinated compounds
|
|
US2009005433A1
|
|
Fluorinated compounds
|
|
US2007154959A1
|
|
Assay system for GLP-2 receptor ligands
|
|
WO2007044796A2
|
|
Pyridazinone compounds as calcilytics
|
|
US2007049578A1
|
|
Cinnamamide compounds as metabotropic glutamate receptor antagonists
|
|
US2007010553A1
|
|
New use
|
|
AU2006201087A1
|
|
Protein formulations
|
|
WO2006066070A2
|
|
Prodrug constructs of pyrimidinone compounds as calcilytics
|
|
EP1809318A2
|
|
Treatment of short bowel syndrome patients with colon-in-continuity
|
|
WO2006042007A2
|
|
Chromenone compounds as calcilytics
|
|
EP1809611A1
|
|
Reversed pyrimidinone compounds as calcilytics
|
|
US2006229470A1
|
|
Calcium receptor-active molecules
|
|
WO2006012603A2
|
|
Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
|
|
CA2555272A1
|
|
Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
|
